[ET Net News Agency, 11 January 2022] CSPC Pharmaceutical Group Limited (01093) said
the "Mitoxantrone Hydrochloride Liposome Injection (10ml:10mg)" developed by CSPC Zhongnuo
Pharmaceutical (Shijiazhuang) Co., Ltd, a subsidiary of the company, has obtained drug
registration approval granted by the National Medical Products Administration of the
People's Republic of China for the treatment of relapsed/refractory peripheral T-cell
lymphoma (PTCL).
It is an anti-tumour nanodrug independently developed by the group and is also the first
mitoxantrone nanodrug launched worldwide, representing a breakthrough in China as there
have been no innovative nanodrugs launched for years. (RC)